RSS Feeds
Search

Press releases

Press releases

Displaying 1..10 of 11 - per page Next page
Order by
Alzheimer’s research to enhance diagnosis
Research into neurodegenerative disease at the Institute of Psychiatry has resulted in the development of a series of biomarkers, or tests, for Alzheimer’s disease. More
King’s spin-out raises £50m
Proximagen, a King’s College London spin-out company focusing on neurodegenerative diseases, has raised £50 million in one of the largest biotech fundraisings in the UK in the past ten years. More
NatureWise announces updates on cancer drug candidate, neurotrophic factors for neurodegenerative disorders
Drug discovery and development firm NatureWise Biotech & Medicals Corp. announces two major updates to its pipeline: NBM-HD-1 for brain cancer and SMA therapy drug candidate, and neurotrophic agents from PPLs for neurodegenerative disease therapy More
Astex achieves second milestone in Alzheimer's drug discovery collaboration with AstraZeneca
Astex Technology, announced that it has received the second milestone payment from AstraZeneca as part of its collaboration to identify novel drugs against a key protein target implicated in Alzheimer's Disease. More
LAY LINE GENOMICS (LLG) grants a non-exclusive license to LUNDBECK for its AD11 transgenic anti-NGF mouse
LAY LINE GENOMICS (LLG) grants a non-exclusive license to LUNDBECK for its AD11 transgenic anti-NGF mouse More
Amarin Corporation Announces Additional Positive Clinical Data For Miraxion To Treat Unresponsive Depression
Consistent data in three Phase IIa clinical trials in depression patients with melancholic characteristics More
Lay Line Genomics licenses AD11 mouse model for Alzheimer's disease to Johnson & Johnson Pharmaceutical Research & Development.
Lay Line Genomics licenses AD11 mouse model for Alzheimer's disease to Johnson & Johnson Pharmaceutical Research & Development. More
Lay Line Genomics SpA announces collaboration targeting Alzheimer's disease with Roche
Lay Line Genomics (LLG) announces today that the company has entered into a collaborative partnership with Roche More
BioXell and Lay Line Genomics announce License Agreement for Anti-TrkA Antibody against Pain
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor More
Neuro3d Raises 20M Euros from Leading European VCs in a second round of financing
Neuro3d is a biopharmaceutical company specialised in the discovery and development of new drugs to treat CNS diseases. More
Displaying 1..10 of 11 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
Sep 2011 - 97 pages - $3,500
Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Feb 2011 - 209 pages - $3,500
Other Central Nervous System Disorders Global Clinical Trials Review, Q1, 2011
Feb 2011 - 75 pages - $1,000
Deals and alliances in central nervous system diseases
Jun 2006 - 1068 pages - $2,495
Will 2011 Spell a Brighter Year for the Pharmaceutical Companies?
Mar 2011 - 6 pages - $500
Company Financials: Acadia Pharmaceuticals Inc.
Jan 2010 - $75
Emerging Technologies: Stem cells
Nov 2011 - 61 pages - $3,800
Sleep Disorders - Pipeline Review, Q3 2011
Jul 2011 - 136 pages - $500
Biomarkers: Technological and Commercial Outlook 2011-2021 - discovering the pharma and diagnostics opportunities
Jun 2011 - 132 pages - $2,350
Central Nervous System Tumors Global Clinical Trial Review, Q4, 2010
Oct 2010 - 53 pages - $1,000
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us